M1 Kliniken AGSTU:M12 +1.31%91 Piotroski F-Score is 9 as of Jun. 28, 2026, which is 50% above its 10-year median of 6.00. GuruFocus rates STU:M12 with a GF Score™ of 91/100 and a GF Value™ of €15.58 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 112 Medical Distribution companies, M1 Kliniken AG ranks better than 99.11% on this metric.
Good Sign:
Piotroski F-Score is 9, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
M1 Kliniken AG has an F-score of 9. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for M1 Kliniken AG's Piotroski F-Score or its related term are showing as below:
STU:M12'
s Piotroski F-Score Range Over the Past 10 Years
Min: 3 Med: 6 Max: 9
Current: 9
During the past 12 years, the highest Piotroski F-Score of M1 Kliniken AG was 9. The lowest was 3. And the median was 6.
M1 Kliniken AG (STU:M12) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
M1 Kliniken AG Piotroski F-Score Related Terms
M1 Kliniken AG Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for M1 Kliniken AG's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:M12 vs MCK, COR, CAH: Piotroski F-Score Comparison
For the Medical Distribution subindustry, M1 Kliniken AG's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
M1 Kliniken AG Piotroski F-Score vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, M1 Kliniken AG's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where M1 Kliniken AG's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
M1 Kliniken AG's current Net Income (TTM) was 22.1.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
M1 Kliniken AG's return on assets of this year was 0.11780173. M1 Kliniken AG's return on assets of last year was 0.07521848.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
M1 Kliniken AG's gearing of this year was 0.02676827. M1 Kliniken AG's gearing of last year was 0.03634477.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
M1 Kliniken AG's current ratio of this year was 2.81979735. M1 Kliniken AG's current ratio of last year was 1.90961033.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
M1 Kliniken AG's number of shares in issue this year was 19.643. M1 Kliniken AG's number of shares in issue last year was 19.643.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
M1 Kliniken AG's gross margin of this year was 0.22677251. M1 Kliniken AG's gross margin of last year was 0.18751769.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
M1 Kliniken AG's asset turnover of this year was 1.9390499. M1 Kliniken AG's asset turnover of last year was 1.5927646.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
1
+
1
+
1
+
1
+
1
+
1
=
9
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
M1 Kliniken AG has an F-score of 9. It is a good or high score, which usually indicates a very healthy situation.
M1 Kliniken AG (STU:M12) has a Piotroski F-Score of 9 as of Jun. 28, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on M1 Kliniken AG and its competitors. This is 50% above median its historical median of 6.00. Over the past decade, M1 Kliniken AG's Piotroski F-Score has ranged from 3.00 to 9.00. According to the industry distribution chart, M1 Kliniken AG ranks #1 out of 112 companies in the Medical Distribution industry, placing it in the top 0.90000000000001%.
Is M1 Kliniken AG's Piotroski F-Score too high?
M1 Kliniken AG's current Piotroski F-Score of 9 is 50% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. The Medical Distribution industry median Piotroski F-Score is 5.00. M1 Kliniken AG's value of 9 is 80% above this industry median. Based on the distribution chart, M1 Kliniken AG ranks #1 out of 112 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, M1 Kliniken AG has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does M1 Kliniken AG's Piotroski F-Score compare to MCK and COR?
According to the Medical Distribution industry distribution chart, M1 Kliniken AG ranks #1 out of 112 companies for Piotroski F-Score. This places M1 Kliniken AG in the top 1% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. M1 Kliniken AG's value of 9 is 80% above this benchmark. Historically, M1 Kliniken AG's own Piotroski F-Score has ranged from 3.00 to 9.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, M1 Kliniken AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Distribution company?
The median Piotroski F-Score among Medical Distribution companies is 5.00, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. M1 Kliniken AG's current Piotroski F-Score of 9 is 80% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on M1 Kliniken AG and its competitors. For the Medical Distribution industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. M1 Kliniken AG's current Piotroski F-Score is 9, which is 50% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is M1 Kliniken AG stock overvalued right now?
Based on GuruFocus' analysis, M1 Kliniken AG (STU:M12) is currently considered Modestly Overvalued. The stock's GF Value™ is €15.58, compared to a current price of €18.54 — trading 19% above its estimated fair value. The current Piotroski F-Score is 9, which is 50% above median its 10-year median of 6.00 and 80% above the Medical Distribution industry median of 5.00. M1 Kliniken AG's overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For M1 Kliniken AG (STU:M12), the current Piotroski F-Score is 9 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is M1 Kliniken AG (STU:M12) Overvalued in 2026?
Based on GuruFocus' analysis, M1 Kliniken AG stock appears to be overvalued.
The current stock price of €18.54 is trading 19% above its estimated GF Value™ of €15.58.
GuruFocus considers M1 Kliniken AG to be Modestly Overvalued.
Key valuation signals for STU:M12:
Piotroski F-Score: 9 (50% above median its 10-year median of 6.00)
GF Value™: €15.58 vs. price of €18.54 (19% above fair value)
Industry Position: 80% above the Medical Distribution median (#1 of 112)
No single metric tells the full story. See the STU:M12 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
M1 Kliniken AG operates in the growing market of aesthetic medicine and plastic surgery and provides aesthetic medical treatments in the self-pay segment. It operates through Beauty and Trade segments. Its activities are focused on providing aesthetic medical treatment. In addition to medical aesthetic treatments, the company also develops and markets pharmaceutical, medical, and medical technology products for aesthetic surgery and cosmetic dermatology. Some of the treatments offered by the group are lip under injection, eyebrow lift, tummy tuck, breast reduction, sweat treatment, liposuction, and others. The organization conducts its business operations in Germany. The majority of its revenue is derived from the Trade segment.
91GF Score
Get the complete analysis for STU:M12
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:M12 has been successfully added to your 
